Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    Pharmacyclics | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Ibrutinib;   Drug: Durvalumab (MEDI4736)
2 Recruiting Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Bortezomib;   Drug: Dexamethasone
3 Recruiting A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Conditions: Renal Cell Carcinoma (RCC);   Urothelial Carcinoma;   Gastric Adenocarcinoma;   Colorectal Adenocarcinoma (CRC)
Interventions: Drug: ibrutinib;   Drug: everolimus;   Drug: docetaxel;   Drug: paclitaxel;   Drug: cetuximab
4 Recruiting Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Ibrutinib;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
5 Recruiting Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
6 Not yet recruiting Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Conditions: Leukemia, Chronic Lymphocytic;   Lymphoma, Small Lymphocytic
Interventions: Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: venetoclax
7 Recruiting informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention:
8 Recruiting Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Placebo
9 Recruiting A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Conditions: Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: MEDI4736
10 Recruiting A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Ibrutinib;   Drug: Ibrutinib + LD-AraC;   Drug: Ibrutinib + Azacitidine
11 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Dexamethasone
12 Recruiting Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma
Condition: Indolent Non-Hodgkin Lymphoma
Interventions: Drug: Ibrutinib;   Drug: GA 101
13 Recruiting Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
Condition: Gastrooesophageal Cancer
Intervention: Drug: ibrutinib
14 Not yet recruiting Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Conditions: Metastatic Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: Ibrutinib;   Drug: Nivolumab
15 Recruiting Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ibrutinib
16 Recruiting First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Ibrutinib;   Drug: Allopurinol;   Drug: Valacyclovir
17 Recruiting Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: obinutuzumab
18 Recruiting Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Ibrutinib
19 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
20 Recruiting Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Ibrutinib

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Indicates status has not been verified in more than two years